Rhythm Pharmaceuticals (RYTM) Retained Earnings (2016 - 2025)
Historic Retained Earnings for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to -$1.3 billion.
- Rhythm Pharmaceuticals' Retained Earnings fell 1729.86% to -$1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 1729.86%. This contributed to the annual value of -$1.2 billion for FY2024, which is 2912.61% down from last year.
- Latest data reveals that Rhythm Pharmaceuticals reported Retained Earnings of -$1.3 billion as of Q3 2025, which was down 1729.86% from -$1.3 billion recorded in Q2 2025.
- Rhythm Pharmaceuticals' 5-year Retained Earnings high stood at -$415.6 million for Q1 2021, and its period low was -$1.3 billion during Q3 2025.
- In the last 5 years, Rhythm Pharmaceuticals' Retained Earnings had a median value of -$808.9 million in 2023 and averaged -$840.4 million.
- As far as peak fluctuations go, Rhythm Pharmaceuticals' Retained Earnings crashed by 1452.37% in 2021, and later plummeted by 3997.48% in 2022.
- Rhythm Pharmaceuticals' Retained Earnings (Quarter) stood at -$528.9 million in 2021, then crashed by 34.24% to -$710.1 million in 2022, then dropped by 26.01% to -$894.7 million in 2023, then dropped by 29.13% to -$1.2 billion in 2024, then dropped by 12.9% to -$1.3 billion in 2025.
- Its Retained Earnings stands at -$1.3 billion for Q3 2025, versus -$1.3 billion for Q2 2025 and -$1.2 billion for Q1 2025.